Stifel Reiterates Hold Rating on Vertex (VRTX), Sees VX-147 a "Big Drug" in Bull-case Scenario
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Hold rating on Vertex (NASDAQ: VRTX), following company's announcement of advancement of VX-147 into ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
